| 1/4 | US=80 / Biol/Mol Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA |
| 2/4 | US=90 / Biol/Mol Eberhard DA. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR mutations, other molecular alterations related to sensitivity to EGFR-targeted therapies in non-small cell lung cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 293-336. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DE QUINASE DE TIROSINA; DIAGNOSTICOS MOLECULARES; MUTACOES; HIBRIDACAO IN SITU FLUORESCENTE; IMUNOHISTOQUIMICA; CANCER DE PULMAO |
| 3/4 | US=90 / Biol/Mol Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA |
| 4/4 | US=21 / Neurologia Vogelbaum M, Thomas T. Contemporary investigational treatments: small molecule agents. In: Barnett GH. High-grade gliomas: diagnosis and treatment. New Jersey: Humana Press, 2007. p. 337-56. (Current Clinical Oncology) ISBN 978-1-58829-511-8. GLIOMA DE ALTO GRAU. TERAPIA; AGENTES MOLECULARES; INIBIDORES DE GLIOMA; FATORES DE CRESCIMENTO; DROGAS DE MOLECULAS PEQUENAS; TERAPIA-ALVO; INIBIDORES DE QUINASE DE TIROSINA |